By integrating the strengths of these two companies, including our global workforce of ~32,000, we aim to deliver increased access to affordable, quality medicines for patients worldwide, regardless of geography or circumstance.

Our global portfolio includes best-in-class, iconic brand-name products as well as global key brands; generics, including branded and complex generics; and over-the-counter offerings across a wide range of therapeutic areas. We are committed to helping create healthier communities worldwide through education, outreach, and better access to treatment.

At Viatris, we have one of the strongest global commercial infrastructures in the industry, with a balanced reach across North America, Europe, the Asia Pacific region, and emerging markets. Our high-quality global manufacturing, scientific excellence, and vast supply chain network mean we are uniquely positioned to improve access to medicine for patients worldwide.

>165

Countries and Territories

~30,000

Colleagues Worldwide

27

Manufacturing, Packaging & Distribution Sites Worldwide

10

Development Centers

Pursuing Policies that Help Patients

Viatris is committed to helping patients everywhere access the medicines they need, at all stages of their lives.

Together, we face evolving healthcare challenges, such as the ongoing worldwide battle against infectious diseases and a global rise in the incidence of noncommunicable diseases (NCDs), in a time of increasingly constrained healthcare resources.

We empower people worldwide to live healthier at every stage of life through access, leadership, and partnership. Our policy vision for a healthy future focuses on tackling existing barriers to healthier lives, building on our unique capabilities to advance holistic health solutions, and working with key stakeholders to achieve better health in the communities we serve.

Policy choices affect all of these challenges. Our policy engagement focuses on tackling existing barriers to healthier lives, building on our unique capabilities to advance holistic health solutions, and working with key stakeholders to achieve better health in the communities we serve.

The global organizations we partner with include:

  • The International Generic and Biosimilar Medicines Association (IGBA) to increase global access to generics and biosimilars
  • TB Alliance to increase access to the molecule pretomanid as part of a two-drug tuberculosis regimen in many low-income countries
  • Medicines for Europe to help increase the health and wellbeing of all Europeans through better access to high quality medicines by removing gaps in access between branded product and generics and biosimilars
  • Gavi, the Bill and Melinda Gates Foundation and the Global Fund to scale up access to affordable HIV treatment in low and lower middle-income countries
  • India’s National Viral Hepatitis Control Program to supply medicine for more than 150,000 patients in more than 11 Indian states
  • Dispensary of Hope, Americares, Direct Relief and other organizations to donate over 1.8 billion doses of medicine in the U.S. and around the world since 2007, including ~120 million does in 2025
Source: Viatris 2025 Sustainability Report